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ARTICLE
A Genetic Association Study of Chromosome 11q22-24 in Two
Different Samples Implicates the FXYD6 Gene, Encoding
Phosphohippolin, in Susceptibility to Schizophrenia
Khalid Choudhury, Andrew McQuillin, Vinay Puri, Jonathan Pimm, Susmita Datta,
Srinivasa Thirumalai, Robert Krasucki, Jacob Lawrence, Nicholas J. Bass, Digby Quested,
Caroline Crombie, Gillian Fraser, Nicholas Walker, Haitham Nadeem, Sophie Johnson, David Curtis,
David St. Clair, and Hugh M. D. Gurling
Previous linkage analyses of families with multiple cases of schizophrenia by us and others have confirmed the involve-
ment of the chromosome 11q22-24 region in the etiology of schizophrenia, with LOD scores of 3.4 and 3.1. We now
report fine mapping of a susceptibility gene in the 11q22-24 region, determined on the basis of a University College
London (UCL) sample of 496 cases and 488 supernormal controls. Confirmation was then performed by the study of
an Aberdeen sample consisting of 858 cases and 591 controls (for a total of 2,433 individuals: 1,354 with schizophrenia
and 1,079 controls). Seven microsatellite or single-nucleotide polymorphism (SNP) markers localized within or near the
FXYD6 gene showed empirically significant allelic associations with schizophrenia in the UCL sample (for D11S1998,
; for rs3168238, ; for TTTC20.2, ; for rs1815774, ; for rs4938445, ; forPp .021 Pp .009 Pp .048 Pp .049 Pp .010
rs4938446, ; for rs497768, ). Several haplotypes were also found to be associated with schizophrenia;Pp .025 Pp .023
for example, haplotype Hap-F21 comprising markers rs10790212-rs4938445-rs497768 was found to be associated with
schizophrenia, by a global permutation test ( ). Positive markers in the UCL sample were then genotyped in thePp .002
Aberdeen sample. Two of these SNPs were found to be associated with schizophrenia in the Scottish sample (for rs4938445,
; for rs497768, ). The Hap-F21 haplotype also showed significant association with schizophrenia in thePp .044 Pp .037
Aberdeen sample, with the same alleles being associated ( ). The FXYD6 gene encodes a protein called “phos-Pp .013
phohippolin” that is highly expressed in regions of the brain thought to be involved in schizophrenia. The protein
functions by modulating the kinetic properties of Na,K-ATPase to the specific physiological requirements of the tissue.
Etiological base-pair changes in FXYD6 or in associated promoter/control regions are likely to cause abnormal function
or expression of phosphohippolin and to increase genetic susceptibility to schizophrenia.
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Schizophrenia (SCZD [MIM #181500]) is a disease charac-
terized by self-neglect, thought disorder, auditory hallu-
cinations, delusions, and bizarre behavior.1 It has a lifetime
prevalence of 0.85% in the United Kingdom. Family, twin,
and adoption studies have confirmed that the disorder is
highly heritable. More than 20 whole-genome linkage
scans of SCZD have demonstrated that there is hetero-
geneity of linkage, involving multiple loci on different
chromosomal regions.2 It is not yet known whether these
loci interact. The linkage studies are interpretable only if
it is accepted that at least some of these loci act indepen-
dently in different families.
Chromosome 11q22 was first implicated in SCZD in a
linkage study of two Japanese pedigrees in which positive
LOD scores between 1.0 and 1.5 were reported with marker
D11S35.3 This was confirmed in a separate study of a large
Canadian pedigree, in which a maximum LOD score of
3.4 was obtained using the same genetic marker, D11S35.4
Later, we published further evidence of linkage to SCZD
at 11q23.3 in a genomewide scan of very large multiply
affected families.5 Overall, we found a 3-point LOD score
of 3.1 with markers D11S925 and D11S934. A LOD score
of 3.2 was found in a single large Icelandic pedigree, again
supporting the existence of locus heterogeneity. The chro-
mosome 11q22-24 region has been shown to be one of the
most well-established linkages to SCZD by a meta-analysis
of 20 genome scans that employed nonparametric rank-
order statistics to show that evidence of linkage at this
region was nonrandom.2 Chromosome 11q22.3-q24.1 was
ranked third of all regions, and, when the different sample
sizes of the 20 SCZD genome scans were taken into ac-
count, it was ranked fourth. This provided considerable
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Table 1. Allelic Association Tests with SCZD at the FXYD6
Locus in the UCL Sample
Marker
and Sample
Marker
Location
(bp)
Previous
Marker
Distance
(bp) x2 Pa
No. of Observed Alleles
for Allelic Base
A C G T
rs11999: 117196128 .91 .340
Control 542 300
Case 521 261
rs869789: 117196596 468 2.75 .097
Control 107 753
Case 138 772
rs4579962: 117197544 948 .03 .860
Control 274 688
Case 266 680
rs529623: 117198465 921 .60 .440
Control 473 395
Case 475 427
rs678776: 117201954 3,489 .00 .975
Control 285 671
Case 282 666
rs479991: 117202168 214 1.17 .280
Control 665 197
Case 715 187
D11S1998 117202941 773 12.60 .021b
rs11216567: 117203693 752 3.25 .072
Control 880 70
Case 829 89
rs10892181: 117204796 1,103 .49 .484
Control 351 609
Case 320 594
rs2019655: 117205088 292 .60 .437
Control 208 664
Case 230 674
rs10790212: 117207900 2,812 .47 .493
Control 640 240
Case 666 232
rs3087563: 117213147 5,247 .09 .763
Control 415 451
Case 422 472
rs3168238: 117214855 1,708 6.80 .009c
Control 76 874
Case 47 887
rs564989: 117214964 109 .30 .584
Control 222 742
Case 226 712
rs12363888: 117218397 3,433 .04 .843
Control 907 55
Case 909 53
rs11608153: 117221873 3,476 .48 .489
Control 821 129
Case 805 115
rs512481: 117224090 2,217 .90 .344
Control 452 494
Case 425 507
rs476130: 117233093 9,003 .64 .423
Control 890 70
Case 853 77
TTTC20.2 117234550 1,457 17.54 .048d
rs7121573: 117235040 490 3.15 .076
Control 382 564
Case 331 579
rs1815774: 117236649 1,609 3.87 .049e
Control 342 528
Case 311 583
rs876798: 117242650 6,001 .45 .503
Control 125 739
Case 123 797
rs876797: 117242957 307 2.94 .086
Control 207 651
Case 186 712
rs873713: 117245126 2,169 2.86 .091
Control 230 710
Case 197 733
(continued)
Table 1. (continued)
Marker
and Sample
Marker
Location
(bp)
Previous
Marker
Distance
(bp) x2 Pa
No. of Observed Alleles
for Allelic Base
A C G T
rs10790218: 117247205 2,079 2.73 .099
Control 374 576
Case 334 602
rs4938445: 117250213 3,008 6.68 .010f
Control 299 579
Case 250 632
rs4938446: 117250259 46 5.00 .025g
Control 296 570
Case 271 655
rs11216598: 117253662 3,403 .07 .798
Control 727 149
Case 771 153
rs631898: 117253688 26 2.31 .128
Control 419 451
Case 466 434
rs11605223: 117254054 366 1.41 .235
Control 490 470
Case 462 494
rs3809043: 117254325 271 .57 .452
Control 929 29
Case 898 34
rs3809042: 117254330 5 .21 .646
Control 27 925
Case 23 899
rs497768: 117255950 1,620 5.21 .023h
Control 416 500
Case 371 553
a Two-tailed significance from x2, with 1 df.2# 2
b P from CLUMP Monte Carlo subtest T2.
c OR 1.64.
d P from CLUMP Monte Carlo subtest T4.
e OR 1.21.
f OR 1.31.
g OR 1.26.
h OR 1.24.
confidence that an SCZD susceptibility locus was likely to
exist in the 11q22-24 region.
Material and Methods
Allelic association studies were performed to fine map an 11q22-
24 SCZD susceptibility gene by detecting linkage disequilibrium
(LD). The University College London (UCL) case-control sample
consisted of 496 unrelated cases and 488 ancestrally matched
controls. Research subjects were selected only if both parents were
English, Scottish, or Welsh, with at least three grandparents hav-
ing the same origins. Subjects were also included if the fourth
grandparent was of another white European origin but were ex-
cluded if one grandparent was of Jewish or non–European Union
(EU) (before the enlargement of the EU in 2004) ancestry. These
data were recorded in an ancestry questionnaire, with confirma-
tion from family histories noted on medical records. U.K. Na-
tional Health Service (NHS) multicenter and local research ethics–
committee approval was obtained, and all participating subjects
signed an approved consent form after reading an information
sheet. Each schizophrenic research subject had received a diag-
nosis and assessment by NHS psychiatrists as part of routine clin-
ical diagnosis and treatment. Those with short-term drug-induced
psychoses, psychoses with either learning disability or head in-
jury, and other symptomatic psychoses were excluded. Schizo-
phrenic subjects were recruited on the basis of having an Inter-
national Classification of Diseases version 10 (ICD10) diagnosis
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Table 2. Fragment Sizes of
Microsatellite Markers at the
FXYD6 Locus in the UCL
Sample
Marker and
Fragment Size
(bp)
No. of Observed
Alleles by
Population
Control Case
D11S1998:
150 60 86
158 1 0
162 2 0
166 38 27
170 405 428
174 275 239
178 75 60
182 7 6
186 1 0
TTTC20.2:
232 8 4
236 3 14
240 22 16
242 3 5
244 130 130
246 11 10
248 97 137
250 54 47
252 113 104
254 65 77
256 75 69
258 60 62
260 31 51
262 60 57
264 12 14
266 46 32
268 3 4
270 17 23
274 9 5
278 2 1
282 1 0
of SCZD recorded in medical case-history notes after clinical in-
terview by NHS psychiatrists. The diagnoses were confirmed by
a senior psychiatrist, usually within 1 wk. Schedule for Affective
Disorders and Schizophrenia–Lifetime Version (SADS-L) interview
was completed for all cases and controls by a research psychia-
trist.6 Schizophrenic subjects were then chosen on the basis of
having received a diagnosis at the “probable level” of the Research
Diagnostic Criteria (RDC).7 Patients with schizoaffective bipolar
disorder or schizomania were not included. All screened control
individuals were also interviewed by a psychiatrist, specifically
for the study, and were selected for having no family history of
SCZD, alcoholism, or bipolar disorder, according to self-report by
the research subject. They were then interviewed with the SADS-
L schedule and were included only if they were found to have
no present or lifetime history of any RDC-defined mental dis-
order. The UCL case-control sample has been used in studies of
other chromosomal regions and has implicated the chromosome
5q33 epsin 4 (CLINT1) gene encoding enthoprotin, the chromo-
some 8p22 PCM1 gene, and the chromosome 1q23 UHMK1 gene
as the cause of SCZD.8–10 The sample has also been used to exclude
association between SCZD and markers at the chromosome 1q23
RGS4 and CAPON (NOS1AP) genes.11,12
Genomic DNA for the UCL case-control sample was extracted
from whole-blood samples by use of standard cell lysis, proteinase
K digestion, and phenol/chloroform ethanol precipitation method,
as described elsewhere.8 All DNA samples were quantified with
Picogreen (Molecular Probes) by use of fluorimetry. Fifteen refer-
ence microsatellite markers at chromosomal loci not thought to
be involved in SCZD were genotyped in a subset of samples (200
cases and 300 controls). This was done to detect genetic hetero-
geneity between the cases and controls and to confirm that the
samples were genetically well matched. In addition, a statistical
test with use of CHECKHET was employed to detect subjects
with an atypical genetic background.13 No evidence of genetic
heterogeneity between cases and controls was found with use of
the reference markers. The CHECKHET test detected two schiz-
ophrenic subjects with abnormal genotypes. These were x-
cluded from the sample before any chromosome 11 markers were
genotyped.
The Aberdeen sample consisted of 858 subjects with SCZD and
591 controls. The cases were recruited through Scottish psychi-
atric hospitals and met DSM-III-R or DSM-IV criteria of SCZD,
with use of an operational criteria checklist (OPCRIT). Diagnosis
of SCZD was confirmed through agreement by two independent
senior psychiatrists on the basis of structured clinical interviews
for DSM-III-R/DSM-IV (SCID) and inspection of psychiatric case
notes. All controls were volunteers recruited through general
practices from the same region of Scotland and were ethnically
matched. The control samples were screened for absence of psy-
chiatric illness. Informed consent was obtained from all patients
and control individuals. A proportion of the Aberdeen sample
was employed elsewhere in tests for genetic association between
NRG1 and SCZD.14
Random markers on chromosome 11q22-24, close to the max-
imum LOD score position in the UCL SCZD family-linkage study,
were initially selected for fine mapping.5 Five of these random
microsatellite markers were genotyped before positive association
with D11S1998 was found. Further nonrandom microsatelliteand
SNP markers close to D11S1998 were then chosen for genotyp-
ing. Microsatellite marker TTTC20.2 was identified from a sim-
ple repeat found in the UCSC Genome Browser database May
2004 assembly. The forward (5′-AGGACCACACTCAGCCTCAC-3′)
and reverse (5′-GGGAAGGAAGGAGAGAGAGAG-3′) primers were
designed using Primer3.15 The primer sequences for D11S29,
D11S4127, D11S1998, D11S939, D11S976, D11S4195, D11S925,
D11S964, D11S836, and D11S934 were obtained from the GDB
Human Genome Database and Ensembl. Microsatellite markers
were genotyped in an initial sample of 443 controls and 480
schizophrenic patients in the UCL sample. PCR amplification of
these markers was performed using an M13-tailed primer and a
second nontailed primer. A third universal M13 sequence primer
labeled with infrared dye IRD700 or IRD800 was used to hybridize
against the M13-tailed locus-specific primer. Microsatellite-marker
fragment sizes were separated and visualized with either of the
two infrared dyes on LiCor 4200L sequencers. Genotyping was
accomplished using SAGA-GT genotyping software (LiCor). The
genotypes were then checked by eye, with all allele calls verified
by a second independent person. Any discrepant genotypes were
repeated. SNPs rs11999, rs869789, rs529623, rs479991, rs2019655,
rs10790212, rs3087563, rs1815774, rs876798, rs876797, r1s-
4938445, rs4938446, rs11216598, and rs631898 were chosen
from Ensembl. Further SNPs—rs4579962, rs678776, rs11216567,
rs10892181, rs3168238, rs564989, rs12363888, rs11608153, rs-
512481, rs476130, rs7121573, rs873713, rs10790218, rs11605223,
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Table 3. Haplotypic Association Tests with SCZD at the FXYD6 Locus in the UCL Sample
No. of Markers
and Haplotype
Reference Haplotype
Global
Empirical
Pa
Alleles
Increasing
in Cases
Estimated
Haplotype
Frequency
(%)
Controls Cases
2:
HAP-F1 rs3168238-rs497768 .0028 T-G 47.9 56.0
3:
HAP-F2 rs564989-rs476130-rs876797 .0043 C-C-C 11.4 14.9
HAP-F3 rs564989-rs476130-rs497768 .0048 T-C-G 41.6 48.7
HAP-F4 rs564989-rs876797-rs873713 .0010 C-C-T 16.9 23.8
HAP-F5 rs476130-rs11605223-rs497768 .0027 C-G-G 11.3 17.1
HAP-F6 rs1815774-rs4938445-rs4938446 .0066 G-G-T 58.1 64.0
HAP-F7 rs11216598-rs11605223-rs497768 .0013 A-G-G 11.4 16.8
HAP-F8 rs11605223-rs3809043-rs497768 .0021 G-C-G 11.5 17.3
4:
HAP-F9 rs3168239-rs564989-rs876797-rs873713 .0013 T-C-C-T 17.9 23.1
HAP-F10 rs3168238-rs12363888-rs11605223-rs497768 .0057 T-C-G-G 10.8 17.2
HAP-F11 rs3168238-rs476130-rs11605223-rs497768 .0026 T-C-G-G 10.7 16.9
HAP-F12 rs3168238-rs11605223-rs3809043-rs497768 .0016 T-G-C-G 10.8 17.3
HAP-F13 rs3168238-rs11605223-rs3809042-rs497768 .0035 T-G-G-G 10.9 17.2
HAP-F14 rs1815774-rs10790218-rs4938445-rs11605223 .0055 G-G-G-G 40.5 46.7
HAP-F15 rs1815774-rs4938445-rs4938446-rs11605223 .0159 G-G-T-G 40.6 47.2
HAP-F16 rs10790218-rs4938445-rs4938446-rs11605223 .0066 G-G-T-G 40.8 46.3
HAP-F17 rs11216598-rs11605223-rs3809043-rs497768 .0019 A-G-C-G 11.4 16.8
a Haplotype-permutation test empirical P, based on 9,999 permutations.
rs3809043, rs3809042, and rs497768—were then selected from
the International HapMap Project with use of the Haploview tag-
ger function.16,17 All SNP markers were determined using KASPar
(KBioscience), a modified Amplifluor SNP-genotyping method. Of
the samples, 17% from each microtitre plate were reduplicated
to detect possible errors and to confirm the reproducibility of
genotypes. The data were then analyzed to confirm Hardy-Wein-
berg equilibrium (HWE). Any markers lacking HWE were repeated
using an alternative Taqman method. Before any association anal-
ysis, the genotype data were assessed using the SCANGROUP pro-
gram in GENECOUNTING.18–20 This program highlights any po-
tential genotyping errors by identifying significant differences in
haplotypic frequencies between any single 96-well microtitre
plate and haplotypic frequencies in all other plates combined. It
is argued that genotyping errors can show up as rare haplotypes
occurring on just a single plate, whereas true haplotypic associ-
ations with disease will appear as differences in haplotype fre-
quencies between cases and controls spread across a number of
plates.
Allelic association analysis with SCZD was performed using a
simple x2 test for biallelic SNPs and by using CLUMP for micro-
satellite markers. CLUMP employs an empirical Monte Carlo test
of significance that does not require further correction for mul-
tiple alleles.21 Subtests of the CLUMP program include T1, Pear-
son’s x2 statistic of the “raw” contingency table; T2, the x2 statistic
of a table with rare alleles grouped together to prevent small
expected cell counts; T3, the largest of the x2 statistics of 2# 2
tables, each of which compares one allele against the rest grouped
together; and T4, the largest of the x2 statistics of all possible
tables, which compares any combination of alleles against2# 2
the rest. To select regions of interest for further investigation, we
took account of the output of the most significant of the four
statistics by use of CLUMP. Likewise, we considered the pointwise
P values for markers individually rather than attempting to derive
an overall P value for the region on the basis of combining results
from multiple markers. The multilocus genotypes were then an-
alyzed for haplotypic association with SCZD by use of GENE-
COUNTING, which computes maximum-likelihood estimates of
haplotype frequencies from phase-unknown case-control data.
The significance of any overall haplotypic association with SCZD
was then obtained with a permutation test.18–20 GENECOUNTING
was also used to calculate pairwise LD between all markers with
use of the LDPAIRS program; this was visualized using LocusView
2.0.
Results
One the five initial randomly selected microsatellites in
the 11q22-24 region, D11S1998, showed allelic association
with SCZD ( ; CLUMP T2) (tables 1 and 2). AfterPp .021
this, other markers to be genotyped were selected non-
randomly by virtue of being very likely to be in LD with
marker D11S1998. From these nonrandom microsatellite
markers, TTTC20.2 was also found to be associated with
SCZD ( ; CLUMP T4). None of the other geno-Pp .048
typed microsatellite markers localized to chromosome
11q22-24 showed association with SCZD (P values are for
CLUMP T1 statistic: for D11S29, ; for D11S4127,Pp .899
; for D11S939, ; for D11S976, ;Pp .521 Pp .460 Pp .393
for D11S4195, ; for D11S925, ; forPp .287 Pp .379
D11S964, ; for D11S836, ; for D11S934,Pp .132 Pp .423
). After microsatellite analysis, SNP markers local-Pp .561
ized near positive markers D11S1998 and TTTC20.2 were
selected for genotyping. SNPs rs3168238 ( ; oddsPp .009
ratio [OR] 1.64), rs1815774 ( ; OR 1.21), rs4938445Pp .049
( ; OR 1.31), rs4938446 ( ; OR 1.26), andPp .010 Pp .025
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Figure 1. LD between markers genotyped in the FXYD6 gene locus in the UCL sample. LD structure (D′) between marker pairs is
indicated by the shaded matrices. Marker positions are given in table 1, and their locations are shown relative to both FXYD genes
displayed above the chromosome bar. The gene structures contain vertical lines representing exons. Genomic positions are in accordance
with the National Center for Biotechnology Information build 35 hg 17 of the human genome assembly. The figure was generated using
LocusView 2.0.
rs497768 ( ; OR 1.24) were all found to be associ-Pp .023
ated with SCZD, with six further SNPs (for rs869789, Pp
; for rs11216567, ; for rs7121573, ;.097 Pp .072 Pp .076
for rs876797, ; for rs873713, ; and forPp .086 Pp .091
rs10790218, ) showing a trend toward association.Pp .099
Tests of three-marker haplotypic association with use of
rs11216598, rs11605223, and rs497768 (Hap-F7) provided
significant evidence of association with SCZD, with a glo-
bal permutation significance of . Several otherPp .0013
two-, three-, and four-marker tests of haplotypic associa-
tion were also significantly positive, as shown in table 3.
Nearly all the genotyped markers that show significant
association with SCZD or a positive trend are localized
within the FXYD domain–containing ion transport reg-
ulator 6 (FXYD6 [MIM *606683]) gene. The exceptions to
these are markers rs869789, D11S1998, and rs11216567,
situated on FXYD2. These three markers show significant
LD with several of the markers in FXYD6. Results of pair-
wise LD statistics between all markers genotyped and their
respective locations are shown in figure 1.
To verify the significance of the positive allelic and hap-
lotypic association found in the UCL sample, replication
was attempted in an Aberdeen case-control sample with
use of SNPs rs869789, rs11216567, rs10790212, rs3168238,
rs876797, rs4938445, and rs497768. With a one-tailed test
of significance, two SNPs were found to show association
with SCZD in the Aberdeen sample (for rs4938445, Pp
; for rs497768, ) (table 4). The allele-fre-.044 Pp .037
quency increase for SNP rs3168238 ( ), althoughPp .074
not significantly associated with SCZD, displayed a trend
in the direction opposite to that found in the UCL sample.
When the data from the UCL and the Aberdeen samples
were combined, three SNP markers showed significant al-
lelic association (for rs869789, ; for rs4938445,Pp .023
; and for rs497768, ), with two furtherPp .002 Pp .005
SNPs displaying a trend toward association (for rs11216567,
, and for rs876797, ) (table 4).Pp .058 Pp .063
The three-marker haplotype rs10790212-rs4938445-
rs497768 (Hap-F21), which produced a global empirical
association in the UCL sample (empirical ), wasPp .002
also found to be replicated in the Aberdeen sample (em-
pirical ). When data from both samples were com-Pp .013
bined, haplotype Hap-F21 exhibited strengthened permu-
tation significance for haplotypic association with SCZD
(empirical ) (table 5). Other significantly asso-Pp .0005
ciated haplotypes in the UCL sample were also found to
be replicated in the Aberdeen sample and when both sam-
ples were combined.
Discussion
The observation of allelic and haplotypic association in
the UCL sample with use of nominal empirically derived
P values and the fact that the same alleles and haplotypes
were associated in the second Aberdeen sample suggest
that it is unlikely that the association between FXYD6 and
SCZD is a false-positive result. The strongest allelic and
haplotypic associations were found with markers within
FXYD6 and not in neighboring genes, which leads us to
believe that this gene was the most likely to be involved
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Table 5. Tests of Haplotypic Association with SCZD at the FXYD6 Locus for
Comparison of UCL, Aberdeen, and Combined Samples
No. of Markers, Haplotype Reference
(Haplotype), and Sample
Global
Empirical
Pa
Alleles
Increasing
in Cases
Estimated
Haplotype
Frequency
(%)
Controls Cases
2:
HAP-F18 (rs10790212-rs4938445):
UCL .0183 C-G 44.7 48.9
Aberdeen .0266 C-G 44.6 49.7
Combined .0093 C-G 44.7 49.4
HAP-F1 (rs3168238-rs497768):
UCL .0028 T-G 47.9 56.0
Aberdeen .1173 T-G 52.0 54.2
Combined .0157 T-G 50.1 54.9
3:
HAP-F19 (rs11216567-rs10790212-rs4938445):
UCL .0038 A-C-G 40.2 44.4
Aberdeen .0453 A-C-G 38.6 44.2
Combined .0687 A-C-G 39.1 44.1
HAP-F20 (rs11216567-rs10790212-rs497768):
UCL .0442 A-C-G 35.2 40.3
Aberdeen .0104 A-C-G 39.3 40.0
Combined .0348 A-C-G 37.5 40.0
HAP-F21 (rs10790212-rs4938445-rs497768):
UCL .0024 C-G-G 23.4 27.9
Aberdeen .0127 C-G-G 25.5 27.6
Combined .0005 C-G-G 24.7 27.7
a Haplotype permutation test empirical P, based on 9,999 permutations.
in the etiology of SCZD. One microsatellite marker in
FXYD2 was found to be associated with SCZD, but none
of the SNPs within FXYD2 were significantly associated in
either the UCL or the Aberdeen samples. We found con-
sistency as to which alleles and haplotypes were associ-
ated with SCZD in the UCL and Aberdeen samples. Even
though an allele at marker rs3168238 showed a trend to
be associated with SCZD with an allele different from the
one that showed significant association in the UCL sam-
ple, it was nevertheless found that the same allele was in
the haplotype showing significant association with SCZD
in the Aberdeen sample.
FXYD6 encodes the protein phosphohippolin and is
part of a family of seven FXYD genes.22 The FXYD proteins
share homology for a single common transmembrane do-
main.23 Each FXYD protein is expressed in a tissue-specific
manner and functions by altering the kinetic activity of
Na,K-ATPase.24 This involves changes in the active Na
and K transports that are based on the specific require-
ments of different cells. The effects of FXYD proteins on
kinetic parameters such as K1/2 Na
, K1/2 K
, and Vmax are
usually approximately twofold.25–27 However, these mod-
erate effects are likely to have long-term physiological im-
portance in maintaining cation homeostasis.28 Regulation
of Na,K-ATPase activity in a tissue- and isoform-specific
manner is essential for tissue functions such as muscle
contraction and neuronal excitability, because of the mod-
ification of its transport properties under changing phys-
iological conditions.29
Phosphohippolin in rats has been found to be expressed
in the neuronal fibers of the lateral habenula nucleus, hy-
pothalamus, amygdaloid body, hippocampus, thalamus,
stria terminalis, cingulum, olfactory bulb, cerebral cortex,
and cerebellum.22,30 The distribution in the cerebellum is
unique, with a predominant expression pattern in the
granule layer of the posterior lobe. Expression studies of
the brain during development show the greatest amount
of phosphohippolin in postnatal 3-wk-old rat brain, with
substantial capacity of phosphohippolin still existing in
the adult brain. This suggests that phosphohippolin may
play an important role in neuronal excitability of the CNS
during postnatal development and in the adult brain.22
The Novartis gene-expression-atlas database (GNF Sym-
Atlas) shows that the expression of FXYD6 in humans is
primarily in the brain, with the highest level of expression
found in the prefrontal cortex, amygdala, hypothalamus,
and occipital lobe. The prominent levels of expression in
regions of the brain thought to be involved in SCZD, as
identified by brain-imaging abnormalities, provide strong
support that the FXYD6 gene increases genetic suscepti-
bility to SCZD.
Confirmation of genetic association with SCZD requires
attention to the statistical power of future case-control
replication studies. The critical issue is the proven pres-
ence of locus heterogeneity for SCZD. The linkage studies
of SCZD have shown strong evidence of heterogeneity,
with different subgroups of families containing different
susceptibility loci. Therefore, any one susceptibility gene
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will increase susceptibility to SCZD in only a minority of
cases. The UCL SCZD sample has the power to detect al-
lelic association of 0.99 at and of 0.91 at ,P ! .05 P ! .001
with the assumption of complete LD between markers and
disease alleles when the minor marker-allele frequency is
!10% and with a difference of 5% in allele frequencies be-
tween cases and controls. If the allele frequency is as high
as 50%, the power is 0.90 at , with a 10% allele-Pp .05
frequency difference. The power of the sample is only 0.41
at for a 5% allele-frequency difference. FurtherPp .05
attempts at replication should aim to have 0.8 power for
a significance of .05; this may require 1,300 cases and
1,300 controls, even with the assumption of complete LD
between markers and disease mutations.
The FXYD6 gene should now be sequenced in schizo-
phrenic subjects from our sample who have inherited the
alleles and haplotypes contributing to the positive asso-
ciation that has been found. This could identify etiological
base-pair changes or mutations affecting the expression
or function of FXYD6 that are involved in the molecu-
lar pathology of SCZD. These may be “private” mutations
not yet identified or genetic variants that are already in
databases.
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